Takeda Pharmaceutical Company Limited (TAK) Financial Statements

Executive TeamFinancials
Shareholders

Takeda Pharmaceutical financial statements at a glance

Takeda Pharmaceutical reported revenue of 4.51 trillion JPY for fiscal year 2026 (ended March 31, 2026), down 1.7% from fiscal year 2025. Net income was -152.39 billion JPY, a net margin of 3.4% loss, and diluted earnings per share were 119.64 JPY.

At the end of fiscal year 2026 it had total assets of 15.51 trillion JPY, total liabilities of 8.08 trillion JPY and shareholders' equity of 7.43 trillion JPY, with cash and short-term investments of 636.94 billion JPY and total debt of 4.88 trillion JPY.

Its operations brought in 1.04 trillion JPY of cash; capital spending was 414.66 billion JPY, leaving free cash flow of 626.77 billion JPY.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in JPY; latest fiscal year ended March 31, 2026.

TAK logo

Takeda Pharmaceutical Company Limited

TAKJapan
Healthcare
JPY (Local)

Income Statement

Annual • JPY

Total Revenue
4.51T
Prev Year: 4.58T
YoY: -1.7%
Operating Revenue
4.51T
Prev Year: 4.58T
YoY: -1.7%
Total Unusual Items
-460.86B
Prev Year: -165.32B
YoY: -178.8%
Normalized EBITDA
1.19T
Prev Year: 1.24T
YoY: -4.1%
Tax Rate for Calcs
0.4
Prev Year: 0.382
YoY: +4.6%
Tax Effect of Unusual Items
-184.34B
Prev Year: -63.21B
YoY: -191.6%
Total Operating Income as Reported
6.22B
Prev Year: 342.59B
YoY: -98.2%
Other Income Expense
-463.03B
Prev Year: -169.31B
YoY: -173.5%
Special Income Charges
-466.99B
Prev Year: -172.92B
YoY: -170.1%
Gain on Sale of Property, Plant and Equipment
165.00M
Prev Year: 363.00M
YoY: -54.5%
Gain on Sale of Business
18.27B
Prev Year: 10.20B
YoY: +79.1%
Other Special Charges
412.23B
Prev Year: 37.57B
YoY: +997.3%
Write-offs
1.36B
Prev Year: 18.38B
YoY: -92.6%
Restructuring and Mergers Acquisition
71.82B
Prev Year: 127.53B
YoY: -43.7%
Equity in Earnings of Affiliates
-2.18B
Prev Year: -3.99B
YoY: +45.4%
Gain on Sale of Securities
6.13B
Prev Year: 7.60B
YoY: -19.3%
Total Other Finance Cost
12.53B
Prev Year: 24.00B
YoY: -47.8%
Depreciation Amortization Depletion
633.54B
Prev Year: 643.23B
YoY: -1.5%
Depreciation and amortization
633.54B
Prev Year: 643.23B
YoY: -1.5%
Amortization
633.54B
Prev Year: 643.23B
YoY: -1.5%
Amortization of Intangibles
633.54B
Prev Year: 643.23B
YoY: -1.5%
Cost of Revenue
1.57T
Prev Year: 1.58T
YoY: -0.5%
Gross Profit
2.93T
Prev Year: 3.00T
YoY: -2.2%
Operating Expense
2.47T
Prev Year: 2.52T
YoY: -1.8%
Selling General and Administrative
1.08T
Prev Year: 1.10T
YoY: -1.9%
Research and Development
675.92B
Prev Year: 730.23B
YoY: -7.4%
Other Operating Expenses
76.00B
Prev Year: 37.05B
YoY: +105.1%
Operating Income
464.45B
Prev Year: 486.06B
YoY: -4.4%
Net Non Operating Interest Income Expense
-143.77B
Prev Year: -141.67B
YoY: -1.5%
Non-operating Interest Income
16.88B
Prev Year: 19.64B
YoY: -14.1%
Non-operating Interest Expense
148.12B
Prev Year: 137.31B
YoY: +7.9%
Pre-tax Income
-142.35B
Prev Year: 175.08B
YoY: -181.3%
Provision for Income Taxes
9.77B
Prev Year: 66.94B
YoY: -85.4%
Net Income Common Stockholders
-152.39B
Prev Year: 107.93B
YoY: -241.2%
Net Income
-152.39B
Prev Year: 107.93B
YoY: -241.2%
Net Income Including Non-Controlling Interests
-152.13B
Prev Year: 108.14B
YoY: -240.7%
Net Income from Continuing Operations
-152.13B
Prev Year: 108.14B
YoY: -240.7%
Noncontrolling Interests
-264.00M
Prev Year: -215.00M
YoY: -22.8%
Diluted NI Available to Com Stockholders
-152.39B
Prev Year: 107.93B
YoY: -241.2%
Basic EPS
121.75
Prev Year: 68.36
YoY: +78.1%
Diluted EPS
119.64
Prev Year: 67.23
YoY: +78.0%
Weighted Average Shares (basic)
1.58B
Prev Year: 1.58B
YoY: -0.2%
Weighted Average Shares (diluted)
1.60B
Prev Year: 1.61B
YoY: -0.2%
Total Expenses
4.04T
Prev Year: 4.10T
YoY: -1.3%
Net Income from Continuing and Discontinued Operation
-152.39B
Prev Year: 107.93B
YoY: -241.2%
Normalized Income
124.12B
Prev Year: 210.04B
YoY: -40.9%
Interest Income
16.88B
Prev Year: 19.64B
YoY: -14.1%
Interest Expense
148.12B
Prev Year: 137.31B
YoY: +7.9%
Net Interest Income
-143.77B
Prev Year: -141.67B
YoY: -1.5%
EBIT
5.77B
Prev Year: 312.39B
YoY: -98.2%
EBITDA
726.89B
Prev Year: 1.07T
YoY: -32.3%
Reconciled Cost of Revenue
1.48T
Prev Year: 1.46T
YoY: +1.5%
Reconciled Depreciation
721.13B
Prev Year: 761.40B
YoY: -5.3%
Net Income from Continuing Operation Net Minority Interest
-152.39B
Prev Year: 107.93B
YoY: -241.2%
Total Unusual Items Excluding Goodwill
-460.86B
Prev Year: -165.32B
YoY: -178.8%
Values in JPY

Takeda Pharmaceutical key figures by fiscal year

FY2026FY2025FY2024FY2023FY2022
Revenue4.5T JPY4.6T JPY$4.3T$4.0T$3.6T
Gross profit2.9T JPY3.0T JPY$2.8T$2.8T$2.5T
Operating income464.5B JPY486.1B JPY$321.0B$554.9B$546.0B
Net income-152.4B JPY107.9B JPY$144.1B$317.0B$230.1B
Diluted EPS119.64 JPY67.23 JPY$91.16$201.94$145.87
Total assets15.5T JPY14.2T JPY$15.1T$14.0T$13.2T
Total liabilities8.1T JPY7.3T JPY$7.8T$7.6T$7.5T
Shareholders' equity7.4T JPY6.9T JPY$7.3T$6.4T$5.7T
Cash and short-term investments636.9B JPY405.6B JPY$472.9B$553.7B$875.0B
Total debt4.9T JPY4.5T JPY$4.8T$4.4T$4.3T
Operating cash flow1.0T JPY1.1T JPY$716.3B$977.2B$1.1T
Capital spending414.7B JPY379.6B JPY$480.7B$633.7B$186.0B
Free cash flow626.8B JPY677.6B JPY$235.6B$343.5B$937.1B

In JPY. Fiscal years as reported by the company; statements on this page go back to fiscal year 2015.

Questions and answers

What was Takeda Pharmaceutical's revenue in fiscal year 2026?

4.51 trillion JPY, down 1.7% from 4.58 trillion JPY in fiscal year 2025.

How much profit does Takeda Pharmaceutical make?

Takeda Pharmaceutical reported net income of -152.39 billion JPY for fiscal year 2026 (3.4% of revenue); operating income was 464.45 billion JPY.

How much cash and debt does Takeda Pharmaceutical have?

At the end of fiscal year 2026: cash and short-term investments of 636.94 billion JPY and total debt of 4.88 trillion JPY.

What is Takeda Pharmaceutical's free cash flow?

626.77 billion JPY in fiscal year 2026 (operating cash flow of 1.04 trillion JPY minus capital spending of 414.66 billion JPY).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube